An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies. An emerging class of anticancer drugs called EZH2 inhibitors may greatly ...

In contrast, the experts noted that several recent FDA approvals introduced first-in-class therapies to the oncology landscape. 1 Among these are menin inhibitors, which block the interaction between ...

A newer class of cancer drugs can delay disease progression or extend survival for breast cancer patients, multiple teams of ...

Please provide your email address to receive an email when new articles are posted on . The wastage cost represents a mean 1.78% of the total cost of treatment. Researchers suggested further study of ...

The treatment of pancreatic cancer, an aggressive form of cancer associated with high mortality rates, is challenging owing to limited options and anticancer screening models. High mortality has been ...

Pretreatment with EZH2 inhibitor (top right) leads to higher recruitment of CAR-T cells (red) into the lymph node tumor compared with control (top left). Pretreatment with EZH2 inhibitor (bottom right ...